Physician profile
John R Rocchi
NPI 1306837091
$3,561.36
in general payments reported to CMS, 2019-2025
42 companies · $826 in 2025
The $826 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $246 · 2021: $48.05 · 2022: $67.31 · 2023: $453 · 2024: $930 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.60 |
| Education | $103.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $624.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $384.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $352.01 | 2019-2025 | Trelegy Ellipta, Bexsero, Penmenvy |
| Abbvie INC. | $263.97 | 2022-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $236.71 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $189.52 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $139.43 | 2019-2025 | Capvaxive, M-M-R II, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $121.84 | 2019-2024 | Takhzyro |
| Lilly USA, LLC | $113.46 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.02 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $85.03 | 2019-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $70.07 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Janssen Pharmaceuticals, INC | $66.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.18 | 2019-2023 | |
| Biocryst US Sales Co., LLC | $58.94 | 2023 | Orladeyo |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rocchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.